LABT (Lakewood-Amedex Biotherapeutics) Net Interest Income: $-0.10 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $2.37
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Net Interest Income?

Lakewood-Amedex Biotherapeutics LABT 8 Net Interest Income is $-0.10 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Lakewood-Amedex Biotherapeutics's net interest income for the three months ended in Mar. 2026 was $-0.04 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.10 Mil.

Lakewood-Amedex Biotherapeutics Net Interest Income Related Terms

Lakewood-Amedex Biotherapeutics Net Interest Income Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Net Interest Income Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Net Interest Income
0.35 0.14 -0.08

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Net Interest Income Get a 7-Day Free Trial 0.01 0.00 -0.03 -0.03 -0.04
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Net Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Interest Income →
What does a Net Interest Income of $-0.10 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Net Interest Income of $-0.10 Mil as of Mar. 2026.
Is Lakewood-Amedex Biotherapeutics' Net Interest Income too high?
Lakewood-Amedex Biotherapeutics' current Net Interest Income is $-0.10 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Net Interest Income compare to CDIO and JAGX?
Lakewood-Amedex Biotherapeutics' Net Interest Income of $-0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Interest Income for a Biotechnology company?
A good Net Interest Income depends on the Biotechnology industry context. However, Net Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Interest Income mean?
A high Net Interest Income can signal that a stock is expensive relative to its fundamentals. Lakewood-Amedex Biotherapeutics's current Net Interest Income is $-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Net Interest Income of $-0.10 Mil. The current Net Interest Income is $-0.10 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Interest Income calculated?
Net Interest Income is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Net Interest Income is $-0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Net Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price